Genetic approach towards a vaccine against malaria

Malaria is a major concern for international health authorities. Millions of people contract it every year in the world due to a parasite of the Plasmodium genus. Due to the complexity of the parasite biology and genetics, there is currently no vaccine against the disease. However, due to the great resistance both to the medicines and to the insecticides used to combat the disease, it has become essential to obtain a vaccine as the necessary tool to prevent transmission and eliminate the disease. The bibliometric data indicate that interest in vaccines has been growing steadily since the 1980s. But nowadays, a powerful tool is used: the Plasmodium genome. This allows us to improve the fight against the disease. Knowing the sequences of the genes that favor the appearance of drug resistance, or those that encode for proteins with greater antigenic response, is a tool that can become fundamental. This article reviews the state of the art on vaccines and genetics, in the fight against malaria, and analyzes the fixed photo that the worldwide research on the disease poses.

[1]  Y. Chinzei,et al.  CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts , 2006, Molecular microbiology.

[2]  R. Sauerwein,et al.  The Human Malaria Parasite Pfs47 Gene Mediates Evasion of the Mosquito Immune System , 2013, Science.

[3]  S. Kappe,et al.  Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection , 2017, Expert review of vaccines.

[4]  O. Doumbo,et al.  A field trial to assess a blood-stage malaria vaccine. , 2011, The New England journal of medicine.

[5]  M. Rodrigues,et al.  Relevance of long-lived CD8+ T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination , 2012, Front. Immun..

[6]  L. von Seidlein,et al.  The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan , 2016, PLoS medicine.

[7]  M. Rosenberg,et al.  Hepatitis B Surface Antigen as Carrier Matrix for the Repetitive Epitope of the Circumsporozoite Protein of Plasmodium Falciparum. , 1988, Bio/Technology.

[8]  A. Lescano,et al.  A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection , 2017, npj Vaccines.

[9]  R. Sinden,et al.  Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP , 2016, Journal of Infectious Diseases.

[10]  Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium , 2017, npj Vaccines.

[11]  J. Baird.  Malaria caused by Plasmodium vivax: recurrent, difficult to treat, disabling, and threatening to life — averting the infectious bite preempts these hazards , 2013 .

[12]  M. Higgins,et al.  A new site of attack for a malaria vaccine , 2018, Nature Medicine.

[13]  A. Folgori,et al.  Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector , 2012, The Journal of infectious diseases.

[14]  K. Mendis,et al.  The neglected burden of Plasmodium vivax malaria. , 2001, The American journal of tropical medicine and hygiene.

[15]  Jianbing Mu,et al.  Plasmodium evasion of mosquito immunity and global malaria transmission: The lock-and-key theory , 2015, Proceedings of the National Academy of Sciences.

[16]  D. Carucci,et al.  DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity , 2013, PloS one.

[17]  S. C. T. P. Rts.  Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial , 2015, The Lancet.

[18]  K. Sell,et al.  Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. , 1979, Bulletin of the World Health Organization.

[19]  B. F. Hall,et al.  malERA: An updated research agenda for malaria elimination and eradication , 2017, PLoS medicine.

[20]  X. Ambroggio,et al.  Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230* , 2016, The Journal of Biological Chemistry.

[21]  D. Webster,et al.  Progress with new malaria vaccines. , 2003, Bulletin of the World Health Organization.

[22]  S. Hoffman,et al.  A public antibody lineage that potently inhibits malaria infection by dual binding to the circumsporozoite protein , 2018, Nature Medicine.

[23]  J. Rayner,et al.  New antigens for a multicomponent blood-stage malaria vaccine , 2014, Science Translational Medicine.

[24]  O. Billker,et al.  Efficacy of a Plasmodium vivax Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic Plasmodium berghei Parasites , 2013, Infection and Immunity.

[25]  Alex B. Miller,et al.  Author Correction: A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite , 2018, Nature Medicine.

[26]  Jonathan E. Allen,et al.  Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.

[27]  Mario Roederer,et al.  Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection , 2017, Proceedings of the National Academy of Sciences.

[28]  J. Dvorin,et al.  Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection , 2014, Science.

[29]  Maya Gokhale,et al.  Scalable metagenomic taxonomy classification using a reference genome database , 2013, Bioinform..

[30]  V. Nussenzweig,et al.  Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge , 2018, Scientific Reports.

[31]  Cho Naing,et al.  Is Plasmodium vivax Malaria a Severe Malaria?: A Systematic Review and Meta-Analysis , 2014, PLoS neglected tropical diseases.

[32]  Cécile Crosnier,et al.  A PfRH5-Based Vaccine Is Efficacious against Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys , 2015, Cell host & microbe.

[33]  Christl A. Donnelly,et al.  Immunity to non-cerebral severe malaria is acquired after one or two infections , 1999, Nature Medicine.

[34]  Francisco G. Montoya,et al.  The research of water use in Spain , 2016 .

[35]  A. Sabchareon,et al.  Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. , 1991, The American journal of tropical medicine and hygiene.

[36]  Timothy William,et al.  World Malaria Report: time to acknowledge Plasmodium knowlesi malaria , 2017, Malaria Journal.

[37]  D. Conway.  Paths to a malaria vaccine illuminated by parasite genomics , 2015, Trends in genetics : TIG.

[38]  G. Bourque,et al.  Mouse ENU Mutagenesis to Understand Immunity to Infection: Methods, Selected Examples, and Perspectives , 2014, Genes.

[39]  J. Baird.  Age-dependent characteristics of protection v. susceptibility to Plasmodium falciparum. , 1998, Annals of tropical medicine and parasitology.

[40]  Sumana Chakravarty,et al.  Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. , 2017, JCI insight.

[41]  Juliana K. Wambua,et al.  Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. , 2017, JCI insight.

[42]  I. McGregor,et al.  Gamma-Globulin and Acquired Immunity to Human Malaria , 1961, Nature.

[43]  J. Craig Venter,et al.  Plasmodium, human and Anopheles genomics and malaria , 2002, Nature.

[44]  A. Cowman,et al.  Vaccines to Accelerate Malaria Elimination and Eventual Eradication. , 2017, Cold Spring Harbor perspectives in medicine.

[45]  Ogobara K. Doumbo,et al.  A Research Agenda to Underpin Malaria Eradication , 2011, PLoS medicine.

[46]  T. Satchwell.  Erythrocyte invasion receptors for Plasmodium falciparum: new and old , 2016, Transfusion medicine.

[47]  Katherine E. Wright,et al.  Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies , 2014, Nature.

[48]  Andrea J. Radtke,et al.  Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate , 2017, Scientific Reports.

[49]  K. Marsh,et al.  Correction: Corrigendum: The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody , 2011, Nature Communications.

[50]  S. Kappe,et al.  A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  David L. Tabb,et al.  A proteomic view of the Plasmodium falciparum life cycle , 2002, Nature.

[52]  A. Folgori,et al.  Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation , 2013, Nature Communications.

[53]  Peter G. Kremsner,et al.  Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. , 2015 .

[54]  R. Miller,et al.  Specificity of protection of man immunized against sporozoite‐induced falciparum malaria , 1973, The American journal of the medical sciences.

[55]  Sumana Chakravarty,et al.  Sterile protection against human malaria by chemoattenuated PfSPZ vaccine , 2017, Nature.